The in-vitro activity of trovafloxacin, a new fluoroquinolone, against Gram-positive bacteria

A. M. Sefton, J. P. Maskell, A. M. Rafay, A. Whiley, J. D. Williams

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

The in-vitro activity of trovafloxacin, a new quinolone, was compared with that of ciprofloxacin, erythromycin, various p-lactam antibiotics and, where appropriate, clindamycin and vancomycin against a range of Gram-positive bacteria including staphylococci (n = 201), Streptococcus pneumoniae (n = 83), β-haemolytic streptococci (n = 46), viridans group streptococci (n = 100), Streptococcus milleri (n = 18) and enterococci (n = 161) by an agar dilution technique. In addition, time-kill studies were performed to estimate the bactericidal activity of trovafloxacin against S. milleri and viridans group streptococci. Trovafloxacin was the most active agent tested against staphylococci. It also showed good activity, at least four-fold and usually eight- to 16-fold that of ciprofloxacin, against all the streptococci. Trovafloxacin showed good activity against vancomycin-sensitive Enterococcus faecalis and Enterococcus faecium, but was less active against the 11 isolates of vancomycin-resistant enterococci. Trovafloxacin showed comparable or superior bactericidal activity to amoxycillin against the S. milleri and viridans group streptococci tested.

Original languageEnglish
Pages (from-to)57-62
Number of pages6
JournalJournal of Antimicrobial Chemotherapy
Volume39
Issue numberSUPPL. B
DOIs
Publication statusPublished - 1997

    Fingerprint

ASJC Scopus subject areas

  • Pharmacology
  • Microbiology

Cite this